Anti-PD1 antibody: a new approach to treatment of lymphomas.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

18 citing papers in PubMed, 1 synthesis or guideline pooled it.

1. Low blood level of tumour suppressor miR-5193 as a target of immunotherapy to PD-L1 in gastric cancer.British journal of cancer · 2024
   Pooled it
2. Overexpression of JMJD6 drives immune evasion via the BRD4-IRF1-PD-L1 axis and promotes malignancy in gastric cancer.Scientific reports · 2025
   Article
3. Immunohistochemical Expression of Programmed Death Ligand 1 in Oral Extranodal Diffuse Large B Cell Lymphoma.European journal of dentistry · 2023
   Article
4. Chemo-free maintenance therapy in adult T-cell acute lymphoblastic leukemia: A case report and literature review.Frontiers in pharmacology · 2023
   Article
5. Roles of NExperimental hematology & oncology · 2022
   Review
6. Advances in Multi-Omics Study of Prognostic Biomarkers of Diffuse Large B-Cell Lymphoma.International journal of biological sciences · 2022
   Review
7. Expression of programmed cell death-ligand 1 in primary testicular diffuse large B cell lymphoma: A retrospective study.Oncology letters · 2019
   Article
8. B7-H4 is highly expressed in aggressive Epstein-Barr virus positive diffuse large B-cell lymphoma and inhibits apoptosis through upregulating Erk1/2 and Akt signalling pathways.Infectious agents and cancer · 2019
   Article
9. Expression of programmed death ligand-1 and programmed death-1 in samples of invasive ductal carcinoma of the breast and its correlation with prognosis.Anti-cancer drugs · 2018
   Article
10. Epstein-Barr virus-associated primary nodal T/NK-cell lymphoma shows a distinct molecular signature and copy number changes.Haematologica · 2018
    Article
11. PD-L1 expression is mainly regulated by interferon gamma associated with JAK-STAT pathway in gastric cancer.Cancer science · 2018
    Article
12. (89)Zr-Oxine Complex PET Cell Imaging in Monitoring Cell-based Therapies.Radiology · 2015
    Article
13. Physiological, Tumor, and Metastatic Niches: Opportunities and Challenges for Targeting the Tumor Microenvironment.Critical reviews in oncogenesis · 2015
    Review
14. How to achieve immune control in chronic hepatitis B?Hepatology international · 2015
    Review
15. Impaired T-Cell Function in B-Cell Lymphoma: A Direct Consequence of Events at the Immunological Synapse?Frontiers in immunology · 2015
    Review
16. Inhibition of mitogen-activated protein kinase pathway can induce upregulation of human leukocyte antigen class I without PD-L1-upregulation in contrast to interferon-γ treatment.Cancer science · 2014
    Article
17. Immune checkpoint inhibitors in clinical trials.Chinese journal of cancer · 2014
    Review
18. Current status of cancer immunotherapy.Journal of stem cells & regenerative medicine · 2014
    Review

Corrections and comments

• Comment on
  Safety and activity of PD1 blockade by pidilizumab in combination with rituximab in patients with relapsed follicular lymphoma: a single group, open-label, phase 2 trial.2014

Authors and funding

2 authors.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as